Explore

Link Cell Therapies Initiates CAR-T Trial and Expands Series A Funding to $90 Million

Link Cell Therapies Initiates CAR-T Trial and Expands Series A Funding to $90 Million

Link Cell Therapies Initiates CAR-T Trial and Expands Series A Funding to $90 Million

UCSF Scientist Awarded $1 Million for KRAS Cancer Breakthrough

UCSF Scientist Awarded $1 Million for KRAS Cancer Breakthrough

Kevan Shokat, a chemical biologist at the University of California, San Francisco (UCSF), has been awarded a $1 million prize by the American Association for Cancer Research. The award recognizes his 2013 discovery of a previously hidden vulnerability in the KRAS gene. This gene is known to be mutated in nearly 90% of pancreatic cancers, making it a significant target for cancer treatment research. Shokat's breakthrough has been hailed as ushering in a 'new era in cancer treatment' due to its potential to lead to the development of drugs specifically targeting this challenging cancer-driving protein. The recognition highlights the impact of fundamental scientific research on advancing medical therapies.

Precede Biosciences Seeks Director for Precision Medicine and IVD Development

Precede Biosciences Seeks Director for Precision Medicine and IVD Development

Precede Biosciences Seeks Director for Precision Medicine and IVD Development

BioNTech to Close Three German Sites Amid Falling COVID-19 Vaccine Demand, Impacting 1,800 Jobs

BioNTech to Close Three German Sites Amid Falling COVID-19 Vaccine Demand, Impacting 1,800 Jobs

BioNTech to Close Three German Sites Amid Falling COVID-19 Vaccine Demand, Impacting 1,800 Jobs

J and Legend Biotech Report Long-Term Survival Benefits for Carvykti in Multiple Myeloma

J and Legend Biotech Report Long-Term Survival Benefits for Carvykti in Multiple Myeloma

Johnson & Johnson and Legend Biotech have announced long-term survival benefits for their CAR T therapy, Carvykti, in patients with multiple myeloma. Data from Cohort A of the Phase 2 CARTITUDE-2 study, presented at the International Myeloma Society annual congress, showed that half of the patients remained alive and without disease progression after a median follow-up of at least five years (60.7 months). In this cohort of 20 patients who received a single dose of Carvykti after at least one prior line of treatment, overall survival at this timepoint was 69.2%. While two additional deaths occurred since the last data cutoff, one due to disease progression and another from breast cancer, none of the deaths in this cohort were deemed related to Carvykti.

Washington University Researchers Advance Blood Cancer Treatment with CRISPR Gene Editing

Washington University Researchers Advance Blood Cancer Treatment with CRISPR Gene Editing

Researchers at Washington University School of Medicine in St. Louis have led a clinical trial demonstrating that genetically modifying donor stem cells before transplantation can make follow-up cancer treatments safer and potentially more effective for aggressive blood cancers. The strategy involves removing a specific protein, CD33, from donor cells using CRISPR gene editing. This modification allows therapies targeting CD33 to attack cancer cells while sparing healthy transplanted cells. The study, conducted at Siteman Cancer Center and 14 other sites in the U.S. and Canada, addresses a major challenge in CAR-T cell therapy for diseases like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These cancers often share proteins with healthy myeloid cells, leading CAR-T cells to destroy healthy cells alongside malignant ones. The trial involved 30 adults with high-risk AML or MDS who received CD33-deleted stem cells, known as tremtelectogene empogeditemcel (trem-cel), developed by Vor Biophar...

Pfizer Seeks AI Oncology Portfolio Lead to Integrate AI-Driven Strategies in Research Pipeline

Pfizer Seeks AI Oncology Portfolio Lead to Integrate AI-Driven Strategies in Research Pipeline

Pfizer Seeks AI Oncology Portfolio Lead to Integrate AI-Driven Strategies in Research Pipeline

Spatial Biology Techniques Advance Understanding of Disease and Drug Development

Spatial Biology Techniques Advance Understanding of Disease and Drug Development

Spatial biology techniques are revolutionizing the understanding of biological processes by mapping the precise distribution of biomolecules within tissues. This approach moves beyond traditional methods that destroy tissue architecture, such as bulk RNA sequencing, which provides a list of components but loses critical spatial context. Spatial transcriptomics, a key technique, analyzes RNA within intact tissue sections, revealing how gene expression varies with location. This allows scientists to create high-definition, 3D geographic maps of tissues, providing insights into complex environments like tumor microenvironments and neurodegenerative diseases. For instance, in oncology, spatial transcriptomics can identify why certain immunotherapy drugs fail by showing that T-cells are physically blocked from reaching cancer cells by fibrotic walls. Beyond RNA, the field of 'Spatial Multi-Omics' is rapidly advancing, enabling the simultaneous mapping of RNA, proteins, and metabolic chemicals on the same tissue...

New Study Links Neuromedin U to Immune Suppression in Aggressive Prostate Cancer

New Study Links Neuromedin U to Immune Suppression in Aggressive Prostate Cancer

A new study conducted by The Wistar Institute has identified a connection between the nervous system and the rapid progression of neuroendocrine prostate cancer (NEPC), an aggressive form of prostate cancer. Published in Oncogene, the research indicates that high levels of neuromedin U (NMU), a type of neurotransmitter, are present in prostate cells during the early stages of NEPC formation. These elevated NMU levels contribute to tumor progression by suppressing the immune response. Specifically, NMU activates neutrophils, which then block the migration of T cells to the prostate, preventing the immune system from attacking the cancer. Unlike typical prostate cancer, which has a high survival rate, NEPC is considered immunologically 'cold,' meaning it does not respond to current treatments, including immunotherapy drugs, due to the absence of T cells within the tumor. The study, led by Dario C. Altieri, M.D., and Michela Perego, Ph.D., utilized a murine model to observe these interactions.

CRISPR Gene Editing Shows Promise in High-Risk Blood Cancer Treatment

CRISPR Gene Editing Shows Promise in High-Risk Blood Cancer Treatment

A new clinical trial is exploring the use of CRISPR gene editing to enhance the safety and effectiveness of post-transplant therapies for aggressive blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These cancers often relapse after stem cell transplantation due to the difficulty of targeting malignant cells without harming healthy donor cells. The trial, conducted by Washington University School of Medicine and Vor Biopharma, involves removing the CD33 protein from donor stem cells using CRISPR technology. This modification aims to allow subsequent targeted therapies to attack cancer cells selectively, sparing healthy blood production. The study's initial findings indicate that all 30 adult patients with high-risk AML or MDS achieved engraftment by day 28, with an average survival of just over 14 months. This approach aligns with previous research demonstrating that gene-editing can enable more selective eradication of malignant cells while preserving healthy donor-der...

Singapore Plans mRNA Vaccine Development for Future Pandemics, Including 'Disease X'

Singapore Plans mRNA Vaccine Development for Future Pandemics, Including 'Disease X'

Singapore has announced its intention to develop and manufacture mRNA vaccines, specifically designed to be adaptable and scalable in response to future unknown pandemics, referred to as 'Disease X.' Health Minister Ong Ye Kung highlighted mRNA technology's flexibility, speed to market, and production efficiency, noting that artificial intelligence (AI) could further accelerate solution iteration. This initiative follows the significant success of mRNA vaccines during the recent global pandemic, which demonstrated the technology's capability to design vaccines rapidly. Decades of research enabled mRNA firms to create vaccines in days, with clinical testing commencing as lockdowns began. The core principle involves injecting messenger RNA (mRNA) within lipid nanoparticles (LNPs) to instruct cells to produce specific proteins, like the coronavirus's spike protein, thereby training the immune system to recognize and combat pathogens. The success of mRNA vaccines has spurred renewed enthusiasm and funding for ...

Gulf Coast Cancer Centers Advocate for Collaboration and NCI Designation to Enhance Patient Care

Gulf Coast Cancer Centers Advocate for Collaboration and NCI Designation to Enhance Patient Care

Directors of two Gulf Coast cancer centers, Raghu Kalluri of the University of Texas Medical Branch Cancer Center and Lucio Miele of Louisiana State University-LCMC Health Cancer Center, are emphasizing the critical role of collaboration and National Cancer Institute (NCI) designation in advancing cancer care. Both centers are actively pursuing NCI designation, viewing it as a benchmark for excellence and a catalyst for improved patient outcomes, early diagnosis, prevention, and access to clinical trials. They envision a 'Gulf Coast Cancer Consortium' to facilitate data sharing, joint clinical trials, and coordinated care across Texas and Louisiana, recognizing the similar demographic and socioeconomic challenges in their contiguous catchment areas. The directors highlighted the need for a team-based approach in modern cancer care, incorporating transdisciplinary collaboration and strategic use of technology, including AI, while addressing concerns about patient privacy and the erosion of public trust in s...